Clinical Trials

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03830411 2021-11-08

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

76 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT03863483 2021-11-08

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

70 enrolled

Nonsquamous Non-Small Cell Lung Cancer

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04967625 2021-07-28

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

23 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04840758 2021-04-12

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Phase 1/2 Unknown

39 enrolled

Multiple Primary Lung Cancer

NCT04612673 2020-11-03

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04513301 2020-08-14

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

70 enrolled

Lung Neoplasms

NCT04486287 2020-07-24

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

44 enrolled

Lung Neoplasms

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04252365 2020-02-05

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT04192682 2020-01-06

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Phase 2/3 Unknown

40 enrolled

Small Cell Lung Carcinoma

NCT04189094 2019-12-06

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

140 enrolled

Lung Neoplasms

NCT04106180 2019-09-26

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

63 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04056949 2019-08-14

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

30 enrolled

Small Cell Lung Carcinoma

NCT03874000 2019-03-19

SMART

43 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative